Nanostructured Lipid Carriers as Potential Drug Delivery Systems for Skin Disorders

Author(s): Tejashree Waghule, Vamshi Krishna Rapalli, Srividya Gorantla, Ranendra Narayan Saha, Sunil Kumar Dubey, Anu Puri, Gautam Singhvi*

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 36 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: Skin diseases affect all the age groups of people and have an impact on patients’ physical, mental, and emotional status. Conventional topical preparation is limited with its efficacy due to low permeation, frequent application, and poor adherence to the therapy for prolong time.

Objective: The objective of this review article is to address the emerging trends of nanotechnology derived lipidic carrier systems for an effective treatment for skin disorders.

Methodology: Various research and review articles from reputed international journals were referred and compiled.

Results and Discussion: Topical drug delivery systems were found to be more effective than oral and parenteral drug delivery systems for treating skin diseases due to targeted localized applications with reduced side effects. Lipid-based nanoparticles have been found to have the potential in treating skin diseases due to the biocompatibility and the versatility of the lipids. Nanostructured lipid carriers (NLCs) have gained much attention in treating skin diseases due to improved stability of the drugs, enhanced skin permeation, retention, and better therapeutic efficacy. The review summarizes the NLCs characteristics and their application for topical delivery of various therapeutics in skin disorders. NLCs have shown great potential in effective drug delivery for the treatment of psoriasis, dermatitis, bacterial infections, and skin cancer. Its cosmetic application has opened a new area for skincare. Furthermore, safety and clinical status revealed its future commercial acceptability.

Conclusion: NLCs have been found as effective lipid nanocarriers for the delivery of topical therapeutics.

Keywords: Nanocarriers, nanostructured lipid carriers, psoriasis, skin diseases, targeted drug delivery, topical drug delivery.

[1]
Seth D, Cheldize K, Brown D, Freeman EF. Global burden of skin disease: inequities and innovations. Curr Dermatol Rep 2017; 6(3): 204-10.
[http://dx.doi.org/10.1007/s13671-017-0192-7 ] [PMID: 29226027]
[2]
Jain S, Barambhe MS, Jain J, Jajoo UN, Pandey N. Prevalence of skin diseases in rural Central India : A community - based, cross - sectional, observational study. J Mahatma Gandhi Inst Med Sci 2016; 21(2): 111-5.
[http://dx.doi.org/10.4103/0971-9903.189537]
[3]
Upreti T. Nanostructured lipid carrier system for the treatment for skin disease-a review. JSM Nanotechnol Nanomedicine 2017; 5(3): 1059-64.
[4]
Griffiths CEM, van de Kerkhof P, Czarnecka-Operacz M. Psoriasis and atopic dermatitis. Dermatol Ther (Heidelb) 2017; 7(s1)(Suppl. 1): 31-41.
[http://dx.doi.org/10.1007/s13555-016-0167-9 ] [PMID: 28150106]
[5]
Holick MF. Photobiology of vitamin D Vitamin D 4th ed. Academic Press 2018; 45-55.
[http://dx.doi.org/10.1016/B978-0-12-809965-0.00004-5]
[6]
Graham HK, Eckersley A, Ozols M, Mellody KT, Sherratt MJ. Human Skin: Composition, structure and visualisation methods.skin biophysics studies in mechanobiology, tissue engineering and biomaterials. Cham : Springer 2019; 1-18.
[http://dx.doi.org/10.1007/978-3-030-13279-8_1]
[7]
Lundborg M, Narangifard A, Wennberg CL, Lindahl E, Daneholt B, Norlén L. Human skin barrier structure and function analyzed by cryo-EM and molecular dynamics simulation. J Struct Biol 2018; 203(2): 149-61.
[http://dx.doi.org/10.1016/j.jsb.2018.04.005 ] [PMID: 29702212]
[8]
Kolarsick PAJ, Kolarsick MA, Goodwin C. Anatomy and physiology of the skin. J Dermatol Nurses Assoc 2011; 3(4): 203-13.
[http://dx.doi.org/10.1097/JDN.0b013e3182274a98]
[9]
Banerjee R. Overcoming the stratum corneum barrier: a nano approach. Drug Deliv Transl Res 2013; 3(3): 205-8.
[http://dx.doi.org/10.1007/s13346-013-0149-8 ] [PMID: 25788129]
[10]
Singhvi G, Hejmady S, Rapalli VK, Dubey SK, Dubey S. Nanocarriers for topical delivery in psoriasis. Delivery of drugs. Germany: Elsevier Inc. 2020; 75-96.
[http://dx.doi.org/10.1016/B978-0-12-817776-1.00004-3]
[11]
Sala M, Diab R, Elaissari A, Fessi H. Lipid nanocarriers as skin drug delivery systems: Properties, mechanisms of skin interactions and medical applications. Int J Pharm 2018; 535(1-2): 1-17.
[http://dx.doi.org/10.1016/j.ijpharm.2017.10.046 ] [PMID: 29111097]
[12]
Gupta M, Agrawal U, Vyas SP. Nanocarrier-based topical drug delivery for the treatment of skin diseases. Expert Opin Drug Deliv 2012; 9(7): 783-804.
[http://dx.doi.org/10.1517/17425247.2012.686490 ] [PMID: 22559240]
[13]
Bangale MS, Mitkare SS, Gattani SG, Sakarkar DM. Recent nanotechnological aspects in cosmetics and dermatological preparations. Int J Pharm Pharm Sci 2012; 4(2): 88-97.
[14]
Girdhar V, Patil S, Banerjee S, Singhvi G. Nanocarriers For drug delivery: Mini review. Curr Nanomed 2018; 8(2): 88-99.
[http://dx.doi.org/10.2174/2468187308666180501092519]
[15]
Mathur V, Satrawala Y, Rajput MS. Physical and chemical penetration enhancers in transdermal drug delivery system. Asian J Pharm 2010; 4(3): 173-83.
[http://dx.doi.org/10.4103/0973-8398.72115]
[16]
Abdelgawad R, Nasr M, Hamza MY, Awad GAS. Topical and systemic dermal carriers for psoriasis. Int J Curr Pharm Rev Res 2016; 8(1): 4-9.
[17]
Kakkar V, Scope SK. Scope of nano delivery for atopic dermatitis. Ann Pharmacol Pharm 2017; 2(27): 2-5.
[18]
Dey S, Datta S, Dasgupta S, Mazumder B, Pathak YV. Lipid nanoparticles for topical application of drugs for skin diseases. Nanobiomaterials in Galenic Formulations and Cosmetics. 1st ed. UK: Elsevier Inc. 2016; 327-62.
[http://dx.doi.org/10.1016/B978-0-323-42868-2.00013-9]
[19]
Razina Z. Seeni, Sangeetha Krishnamurthy JMC. Nanoparticles for improved topical drug delivery for skin diseases. perspectives in micro- and nanotechnology for biomedical applications. Imperial College Press 2016; 275-94.
[20]
Singhvi G, Banerjee S, Khosa A. Lyotropic liquid crystal nanoparticles: A novel improved lipidic drug delivery system. Organic Materials as Smart Nanocarriers for Drug Delivery. UK: William Andrew Publishing 2018; 471-517.
[http://dx.doi.org/10.1016/B978-0-12-813663-8.00011-7]
[21]
Singhvi G, Dubey SK, Patil S, Girdhar V. Nanocarriers for topical drug delivery: Approaches and advancements. Nanosci Nanotechnol Asia 2019; 08(3): 329-36.
[http://dx.doi.org/10.2174/2210681208666180320122534]
[22]
Jain S, Krishna Cherukupalli S, Mahmood A, et al. Emerging nanoparticulate systems: Preparation techniques and stimuli responsive release characteristics. J Appl Pharm Sci 2019; 9(08): 130-43.
[http://dx.doi.org/10.7324/JAPS.2019.90817]
[23]
Waghule T, Singhvi G, Dubey SK, et al. Microneedles: A smart approach and increasing potential for transdermal drug delivery system. Biomed Pharmacother 2019; 109: 1249-58.
[http://dx.doi.org/10.1016/j.biopha.2018.10.078 ] [PMID: 30551375]
[24]
Singhvi G, Manchanda P, Hans N, Dubey SK, Gupta G. Microsponge: An emerging drug delivery strategy. Drug Dev Res 2019; 80(2): 200-8.
[http://dx.doi.org/10.1002/ddr.21492 ] [PMID: 30456763]
[25]
Singhvi G, Manchanda P, Krishna Rapalli V, Kumar Dubey S, Gupta G, Dua K. MicroRNAs as biological regulators in skin disorders. Biomed Pharmacother 2018; 108: 996-1004.
[http://dx.doi.org/10.1016/j.biopha.2018.09.090 ] [PMID: 30372911]
[26]
Fang C-L, Al-Suwayeh SA, Fang JY. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat Nanotechnol 2013; 7(1): 41-55.
[http://dx.doi.org/10.2174/187221013804484827 ] [PMID: 22946628]
[27]
Eastoe J, Hollamby MJ, Hudson L. Recent advances in nanoparticle synthesis with reversed micelles. Adv Colloid Interface Sci 2006; 128-130: 5-15.
[http://dx.doi.org/10.1016/j.cis.2006.11.009 ] [PMID: 17254535]
[28]
Purohit DK, Nandgude TD, Poddar SS. Nano-lipid carriers for topical application: Current scenario. Asian J Pharm 2016; 10(1): 1-9.
[29]
Patidar A, Thakur DS, Kumar P, Verma J. A review on novel lipid based nanocarriers. Int J Pharm Pharm Sci 2010; 2(4): 30-5.
[30]
Kaur S, Nautyal U, Singh R, Singh S, Devi A. Nanostructure Lipid Carrier (NLC): the new generation of lipid nanoparticles. Asian Pac J Heal Sci 2015; 2(22): 76-93.
[http://dx.doi.org/10.21276/apjhs.2015.2.2.14]
[31]
Natarajan J, Vvsr K, De A. Nanostructured Lipid Carrier (NLC): A Promising drug delivery system. Glob J Nanomedicine 2017; 1(5)555575
[32]
Peddinti S. Pharmaceutics and nanotechnology nanostructured lipid carriers as a drug carrier. Res Rev J Pharm Nanotechnol 2016; 4: 68-74.
[33]
Sharma A, Baldi A. Nanostructured lipid carriers: A review. J Dev Drugs 2018; 7(1): 1-12.
[34]
Patel DK, Kesharwani R, Kumar V. Lipid nanoparticle topical and transdermal delivery: A review on production, penetration mechanism to skin. Int J Pharm Investig 2019; 9(4): 148-53.
[http://dx.doi.org/10.5530/ijpi.2019.4.28]
[35]
Zhang T, Chen J, Zhang Y, Shen Q, Pan W. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. Eur J Pharm Sci 2011; 43(3): 174-9.
[http://dx.doi.org/10.1016/j.ejps.2011.04.005 ] [PMID: 21530654]
[36]
Rapalli VK, Kaul V, Gorantla S, et al. UV Spectrophotometric method for characterization of curcumin loaded nanostructured lipid nanocarriers in simulated conditions: Method development, in-vitro and ex-vivo applications in topical delivery. Spectrochim Acta A Mol Biomol Spectrosc 2020; 224117392
[http://dx.doi.org/10.1016/j.saa.2019.117392 ] [PMID: 31330421]
[37]
Zhai Y, Zhai G. Advances in lipid-based colloid systems as drug carrier for topic delivery. J Control Release 2014; 193: 90-9.
[http://dx.doi.org/10.1016/j.jconrel.2014.05.054 ] [PMID: 24939745]
[38]
Mahant S, Rao R, Nanda S. Nanostructured lipid carriers: Revolutionizing skin care and topical therapeutics. Design of Nanostructures for Antimicrobial, Antioxidant and Nutraceutical Applications. UK: Elsevier Inc. 2018; 97-136.
[39]
Teeranachaideekul V, Souto EB, Junyaprasert VB, Müller RH. Cetyl palmitate-based NLC for topical delivery of Coenzyme Q(10) - development, physicochemical characterization and in vitro release studies. Eur J Pharm Biopharm 2007; 67(1): 141-8.
[http://dx.doi.org/10.1016/j.ejpb.2007.01.015 ] [PMID: 17346953]
[40]
Shreya AB, Raut SY, Managuli RS, Udupa N, Mutalik S. Active targeting of drugs and bioactive molecules via oral administration by ligand-conjugated lipidic nanocarriers: Recent Advances. AAPS PharmSciTech 2018; 20(1): 15.
[http://dx.doi.org/10.1208/s12249-018-1262-2 ] [PMID: 30564942]
[41]
Khosa A, Saha RN, Singhvi G. Drug delivery to the brain. Grumezescu AM, editor Nanomaterials for Drug Delivery and Therapy. Elsevier Inc. 2019; 461-514.
[http://dx.doi.org/10.1016/B978-0-12-816505-8.00005-9]
[42]
Dua K, Rapalli VK, Shukla SD, et al. Multi-drug resistant Mycobacterium tuberculosis & oxidative stress complexity: Emerging need for novel drug delivery approaches. Biomed Pharmacother 2018; 107: 1218-29.
[http://dx.doi.org/10.1016/j.biopha.2018.08.101 ] [PMID: 30257336]
[43]
Shah PP, Desai PR, Channer D, Singh M. Enhanced skin permeation using polyarginine modified nanostructured lipid carriers. J Control Release 2012; 161(3): 735-45.
[http://dx.doi.org/10.1016/j.jconrel.2012.05.011 ] [PMID: 22617521]
[44]
Malgarim Cordenonsi L, Faccendini A, Catanzaro M, et al. The role of chitosan as coating material for nanostructured lipid carriers for skin delivery of fucoxanthin. Int J Pharm 2019; 567118487
[http://dx.doi.org/10.1016/j.ijpharm.2019.118487 ] [PMID: 31271813]
[45]
Bhattacharjee S. DLS and zeta potential - What they are and what they are not? J Control Release 2016; 235: 337-51.
[http://dx.doi.org/10.1016/j.jconrel.2016.06.017 ] [PMID: 27297779]
[46]
Mahmood A, Krishna V, Waghule T, et al. Spectrochimica acta part A : Molecular and biomolecular spectroscopy. UV spectrophotometric method for simultaneous estimation of betamethasone valerate and tazarotene with absorption factor method : Application for in-vitro and ex-vivo characterization of. Spectrochim Acta A Mol Biomol Spectrosc 2020; 235118310
[http://dx.doi.org/10.1016/j.saa.2020.118310 ] [PMID: 32251894]
[47]
Banerjee S, Singhvi G, Khosa A. In vitro Lipolysis: An indispensable tool for the development of IVIVC of lipid based drug delivery systems. Drug Deliv Lett 2017; 7(3): 151-6.
[http://dx.doi.org/10.2174/2210303107666170929112835]
[48]
Singhvi G. In-vitro and In-vivo Correlations [IVIVCs] for Lipid Based Nano Formulations. Drug Deliv Lett 2017; 7(3): 2210.
[http://dx.doi.org/10.2174/221030310703171106114616]
[49]
Nair A, Jacob S, Al-dhubiab B, Attimarad M, Harsha S. Basic considerations in the dermatokinetics of topical formulations. Braz J Pharm Sci 2013; 49(3): 423-34.
[http://dx.doi.org/10.1590/S1984-82502013000300004]
[50]
Abd E, Yousef SA, Pastore MN, et al. Skin models for the testing of transdermal drugs. Clin Pharmacol 2016; 8: 163-76.
[http://dx.doi.org/10.2147/CPAA.S64788 ] [PMID: 27799831]
[51]
Jin H, He R, Oyoshi M, Geha RS. Animal models of atopic dermatitis. J Invest Dermatol 2009; 129(1): 31-40.
[http://dx.doi.org/10.1038/jid.2008.106 ] [PMID: 19078986]
[52]
Kelidari HR, Moazeni M, Babaei R, et al. Improved yeast delivery of fluconazole with a nanostructured lipid carrier system. Biomed Pharmacother 2017; 89: 83-8.
[http://dx.doi.org/10.1016/j.biopha.2017.02.008 ] [PMID: 28222399]
[53]
Tian B, Yan Q, Wang J, Ding C, Sai S. Enhanced antifungal activity of voriconazole-loaded nanostructured lipid carriers against Candida albicans with a dimorphic switching model. Int J Nanomedicine 2017; 12: 7131-41.
[http://dx.doi.org/10.2147/IJN.S145695 ] [PMID: 29026306]
[54]
Song SH, Lee KM, Kang JB, Lee SG, Kang MJ, Choi YW. Improved skin delivery of voriconazole with a nanostructured lipid carrier-based hydrogel formulation. Chem Pharm Bull (Tokyo) 2014; 62(8): 793-8.
[http://dx.doi.org/10.1248/cpb.c14-00202 ] [PMID: 25087631]
[55]
Waghule T, Rapalli VK, Singhvi G, et al. Voriconazole loaded nanostructured lipid carriers based topical delivery system: QbD based designing, characterization, in-vitro and ex-vivo evaluation. J Drug Deliv Sci Technol 2019; 52: 303-15.
[http://dx.doi.org/10.1016/j.jddst.2019.04.026]
[56]
Sanap GS, Mohanta GP. Design and evaluation of miconazole nitrate loaded Nanostructured Lipid Carriers (NLC) for improving the Antifungal therapy. J Appl Pharm Sci 2013; 3(01): 46-54.
[57]
Khalil RM, Elbary AA. Formulation and characterization of nystatin- loaded nanostructured lipid carriers for topical delivery against cutaneous candidiasis. Br J Pharm Res 2013; 2014(4): 490-512.
[http://dx.doi.org/10.9734/BJPR/2014/7055]
[58]
Sharma A, Sood A, Mehta V, Malairaman U. Formulation and physicochemical evaluation of nanostructured lipid carrier for codelivery of clotrimazole and ciprofloxacin. Asian J Pharm Clin Res 2016; 9(3): 356-60.
[59]
Garcia-Orue I, Gainza G, Girbau C, et al. LL37 loaded nanostructured lipid carriers (NLC): A new strategy for the topical treatment of chronic wounds. Eur J Pharm Biopharm 2016; 108: 310-6.
[http://dx.doi.org/10.1016/j.ejpb.2016.04.006 ] [PMID: 27080206]
[60]
Pinto MF, Moura CC, Nunes C, Segundo MA, Costa Lima SA, Reis S. A new topical formulation for psoriasis: development of methotrexate-loaded nanostructured lipid carriers. Int J Pharm 2014; 477(1-2): 519-26.
[http://dx.doi.org/10.1016/j.ijpharm.2014.10.067 ] [PMID: 25445970]
[61]
Agrawal Y, Petkar KC, Sawant KK. Development, evaluation and clinical studies of Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis. Int J Pharm 2010; 401(1-2): 93-102.
[http://dx.doi.org/10.1016/j.ijpharm.2010.09.007 ] [PMID: 20858539]
[62]
Pradhan M, Singh D, Murthy SN, Singh MR. Design, characterization and skin permeating potential of Fluocinolone acetonide loaded nanostructured lipid carriers for topical treatment of psoriasis. Steroids 2015; 101: 56-63.
[http://dx.doi.org/10.1016/j.steroids.2015.05.012 ] [PMID: 26049018]
[63]
Nam SH, Ji XY, Park J. Investigation of tacrolimus loaded nanostructured lipid carriers for topical drug delivery. Bull Korean Chem Soc 2011; 32(3): 956-60.
[http://dx.doi.org/10.5012/bkcs.2011.32.3.956]
[64]
Nagaich U, Gulati N. Nanostructured lipid carriers (NLC) based controlled release topical gel of clobetasol propionate: design and in vivo characterization. Drug Deliv Transl Res 2016; 6(3): 289-98.
[http://dx.doi.org/10.1007/s13346-016-0291-1 ] [PMID: 27072979]
[65]
Abdel-Salam FS, Mahmoud AA, Ammar HO, et al. Nanostructured lipid carriers as semisolid topical delivery formulations for diflucortolone valerate. J Liposome Res 2017; 27(1): 41-55.
[http://dx.doi.org/10.3109/08982104.2016.1149866 ] [PMID: 26956098]
[66]
Abdel-Salam FS, Ammar HO, Elkheshen SA, Mahmoud AA. Anti-inflammatory sunscreen nanostructured lipid carrier formulations. J Drug Deliv Sci Technol 2017; 37: 13-9.
[http://dx.doi.org/10.1016/j.jddst.2016.10.014]
[67]
Almousallam M, Moia C, Zhu H. Development of nanostructured lipid carrier for dacarbazine delivery. Int Nano Lett 2015; 5(4): 241-8.
[http://dx.doi.org/10.1007/s40089-015-0161-8]
[68]
Rajinikanth PS, Chellian J. Development and evaluation of nanostructured lipid carrier-based hydrogel for topical delivery of 5-fluorouracil. Int J Nanomedicine 2016; 11: 5067-77.
[http://dx.doi.org/10.2147/IJN.S117511 ] [PMID: 27785014]
[69]
Qidwai A, Khan S, Md S, et al. Nanostructured lipid carrier in photodynamic therapy for the treatment of basal-cell carcinoma. Drug Deliv 2016; 23(4): 1476-85.
[http://dx.doi.org/10.3109/10717544.2016.1165310 ] [PMID: 26978275]
[70]
Tofani RP, Sumirtapura YC, Darijanto ST. Formulation, characterisation, and in vitro skin diffusion of nanostructured lipid carriers for deoxyarbutin compared to a nanoemulsion and conventional cream. Sci Pharm 2016; 84(4): 634-45.
[http://dx.doi.org/10.3390/scipharm84040634 ] [PMID: 28656942]
[71]
Pamudji JS, Mauludin R, Indriani N. Development of nanostructutred lipid carrier formulation containing of ratinyl parmitate. Int J Pharm Pharm Sci 2016; 8(2): 256-60.
[72]
Li B, Ge ZQ. Nanostructured lipid carriers improve skin permeation and chemical stability of idebenone. AAPS PharmSciTech 2012; 13(1): 276-83.
[http://dx.doi.org/10.1208/s12249-011-9746-3 ] [PMID: 22234598]
[73]
Leelapornpisid P, Chansakaow S, Na-boonlong S, Jantrawut P. Development of cream containing Nanostructured Lipid carriers loaded marigold (TAGETES ERECTA LINN) flowers extract for anti-wrinkles application. Int J Pharm Pharm Sci 2014; 6(5): 5-9.
[74]
Andrea P, Vidal C, Garcia M, Espina M, Calpena A. Vitiligo and Skincare Physicians Meeting. Scientific Program 2016; 7(5): 9554.
[75]
Souto EB, Müller RH. SLN and NLC for topical delivery of ketoconazole. J Microencapsul 2005; 22(5): 501-10.
[http://dx.doi.org/10.1080/02652040500162436 ] [PMID: 16361193]
[76]
Lewies A, Wentzel JF, Jordaan A, Bezuidenhout C, Du Plessis LH. Interactions of the antimicrobial peptide nisin Z with conventional antibiotics and the use of nanostructured lipid carriers to enhance antimicrobial activity. Int J Pharm 2017; 526(1-2): 244-53.
[http://dx.doi.org/10.1016/j.ijpharm.2017.04.071 ] [PMID: 28461263]
[77]
Cortesi R, Valacchi G, Muresan XM, et al. Nanostructured lipid carriers (NLC) for the delivery of natural molecules with antimicrobial activity: production, characterisation and in vitro studies. J Microencapsul 2017; 34(1): 63-72.
[http://dx.doi.org/10.1080/02652048.2017.1284276 ] [PMID: 28097914]
[78]
Rapalli VK, Singhvi G, Dubey SK, Gupta G, Chellappan DK, Dua K. Emerging landscape in psoriasis management: From topical application to targeting biomolecules. Biomed Pharmacother 2018; 106: 707-13.
[http://dx.doi.org/10.1016/j.biopha.2018.06.136 ] [PMID: 29990862]
[79]
Chandra A, Joshi K, Aggarwal G. Topical nano drug delivery for treatment of psoriasis: Progressive and novel delivery. Asian J Pharm 2018; 12(3): S835-48.
[80]
Chovatiya R, Silverberg JI. Pathophysiology of atopic dermatitis and psoriasis: implications for management in children. Children (Basel) 2019; 6(10): 108.
[http://dx.doi.org/10.3390/children6100108 ] [PMID: 31590274]
[81]
Lin YK, Huang ZR, Zhuo RZ, Fang JY. Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery. Int J Nanomedicine 2010; 5(1): 117-28.
[PMID: 20309398]
[82]
Arora R, Katiyar SS, Kushwah V, Jain S. Solid lipid nanoparticles and nanostructured lipid carrier-based nanotherapeutics in treatment of psoriasis: a comparative study. Expert Opin Drug Deliv 2017; 14(2): 165-77.
[http://dx.doi.org/10.1080/17425247.2017.1264386 ] [PMID: 27882780]
[83]
Akhtar N, Verma A, Pathak K. Exploring preclinical and clinical effectiveness of nanoformulations in the treatment of atopic dermatitis: Safety aspects and patent reviews. Bull Fac Pharm Cairo Univ 2017; 55(1): 1-10.
[http://dx.doi.org/10.1016/j.bfopcu.2016.12.003]
[84]
Peng W, Novak N. Pathogenesis of atopic dermatitis. Clin Exp Allergy 2015; 45(3): 566-74.
[http://dx.doi.org/10.1111/cea.12495 ] [PMID: 25610977]
[85]
Rowany T. Kakwere, Charles Poku-Mensah, Leigh J Mack, Lisa Admans, Vinicius Tieppo Francio TLB. Tacrolimus nanomedicince in the treatment of atopic dermatitis. MOJ Cell Sci Rep 2017; 4(1): 4-6.
[86]
Keck CM, Anantaworasakul P, Patel M, et al. A new concept for the treatment of atopic dermatitis: silver-nanolipid complex (sNLC). Int J Pharm 2014; 462(1-2): 44-51.
[http://dx.doi.org/10.1016/j.ijpharm.2013.12.044 ] [PMID: 24378329]
[87]
Qadir MI. Skin cancer: Etiology and management. Pak J Pharm Sci 2016; 29(3): 999-1003.
[PMID: 27166545]
[88]
Howard MD, Su JC, Chong AH. Skin cancer following solid organ transplantation: A review of risk factors and models of care. Am J Clin Dermatol 2018; 19(4): 585-97.
[http://dx.doi.org/10.1007/s40257-018-0355-8 ] [PMID: 29691768]
[89]
Skin cancer statistics | World Cancer Research Fund Available from: https://www.wcrf.org/dietandcancer/cancer-trends/skin-cancer-statistics
[90]
Vyas A, Das SK, Singh D, et al. Recent Nanoparticulate approaches of drug delivery for skin cancer. Trends Appl Sci Res 2012; 7(8): 620-35.
[http://dx.doi.org/10.3923/tasr.2012.620.635]
[91]
Joseph E, Singhvi G. Multifunctional nanocrystals for cancer therapy: a potential nanocarrier. Grumezescu AM, editor Nanomaterials for Drug Delivery and Therapy. Elsevier Inc. 2019; 91-116.
[http://dx.doi.org/10.1016/B978-0-12-816505-8.00007-2]
[92]
Venâncio JH, Andrade LM, Esteves NLS, et al. Topotecan-loaded lipid nanoparticles as a viable tool for the topical treatment of skin cancers. J Pharm Pharmacol 2017; 69(10): 1318-26.
[http://dx.doi.org/10.1111/jphp.12772 ] [PMID: 28703281]
[93]
Aliasgharlou L, Ghanbarzadeh S, Azimi H, Zarrintan MH, Hamishehkar H. Nanostructured lipid carrier for topical application of N-acetyl glucosamine. Adv Pharm Bull 2016; 6(4): 581-7.
[http://dx.doi.org/10.15171/apb.2016.072 ] [PMID: 28101465]
[94]
Sanad RA, Abdelmalak NS, Elbayoomy TS, Badawi AA. Formulation of a novel oxybenzone-loaded nanostructured lipid carriers (NLCs). AAPS PharmSciTech 2010; 11(4): 1684-94.
[http://dx.doi.org/10.1208/s12249-010-9553-2 ] [PMID: 21107771]
[95]
Gan L, Zhang C, Wu F, Li H, Zhang WP, Zhang Q. Microencapsulated nanostructured lipid carriers as delivery system for rutin. Mater Technol 2018; 33(5): 357-63.
[http://dx.doi.org/10.1080/10667857.2018.1446406]
[96]
Malik DS, Kaur G. Exploring therapeutic potential of azelaic acid loaded NLCs for the treatment of acne vulgaris. J Drug Deliv Sci Technol 2020; 55101418
[http://dx.doi.org/10.1016/j.jddst.2019.101418]
[97]
Nordin N, Yeap SK, Zamberi NR, et al. Characterization and toxicity of citral incorporated with nanostructured lipid carrier. PeerJ 2018; 6e3916
[http://dx.doi.org/10.7717/peerj.3916 ] [PMID: 29312812]
[98]
Müller RH, Petersen RD, Hommoss A, Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 2007; 59(6): 522-30.
[http://dx.doi.org/10.1016/j.addr.2007.04.012 ] [PMID: 17602783]
[99]
Mishra DK, Shandilya R, Mishra PK. Lipid based nanocarriers : a translational perspective. Nanomedicine Nanotechnology. Biol Med (Aligarh) 2018; 14(7): 2023-50.
[100]
Feng J, Markwalter CE, Tian C, Armstrong M, Prud’homme RK, Prud RK. Translational formulation of nanoparticle therapeutics from laboratory discovery to clinical scale. J Transl Med 2019; 17(1): 200.
[http://dx.doi.org/10.1186/s12967-019-1945-9 ] [PMID: 31200738]
[101]
Dormont F, Rouquette M, Mahatsekake C, et al. Translation of nanomedicines from lab to industrial scale synthesis: The case of squalene-adenosine nanoparticles. J Control Release 2019; 307: 302-14.
[http://dx.doi.org/10.1016/j.jconrel.2019.06.040 ] [PMID: 31260754]
[102]
Hu C, Qian A, Wang Q, et al. Industrialization of lipid nanoparticles: From laboratory-scale to large-scale production line. Eur J Pharm Biopharm 2016; 109: 206-13.
[http://dx.doi.org/10.1016/j.ejpb.2016.10.018 ] [PMID: 27793754]
[103]
Rapalli VK, Khosa A, Singhvi G, Girdhar V, Jain R, Dubey SK. Application of QbD principles in nanocarrier-based drug delivery systems. pharmaceutical quality by design. Academic Press 2019; 255-96.
[http://dx.doi.org/10.1016/B978-0-12-815799-2.00014-9]


open access plus

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 36
Year: 2020
Published on: 14 June, 2020
Page: [4569 - 4579]
Pages: 11
DOI: 10.2174/1381612826666200614175236

Article Metrics

PDF: 54
HTML: 9
EPUB: 1
PRC: 1